Expand your understanding of cardiometabolic care by exploring the complex relationship between excess adiposity, cardiovascular disease, and diabetes. This course will equip you with practical knowledge of emerging therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, and collaborative care strategies to help optimize outcomes for patients with obesity and cardiometabolic disease.
Learning Objectives
- Explain the pathophysiology of excess adiposity, cardiometabolic dysfunction, and cardiovascular risk in patients with and without diabetes
- Explore current and future trends in cardiometabolic pharmacologic management
- Review pharmacologic mechanism of action of guideline-directed therapies including GLP-1 receptor agonists, SGLT2 inhibitors
- Discuss care models that bridge cardiology, endocrinology, nutrition, and behavioral health to address obesity as a chronic disease
CE certificate available upon successful completion of the post-test and program evaluation.
MD, MS
Accreditation:
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.
